Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 113 entries
View as:

A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Given by Mouth and Into a Vein as an Injection

Phase: N/A Priority: Normal
NCT ID: NCT03787186 Org: User:
Start: 11/09/18 End: 01/17/19 Due: 01/17/20

Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients

Phase: N/A Priority: Normal
NCT ID: NCT01668641 Org: User:
Start: 05/31/12 End: 10/31/12 Due: 10/31/13

A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059

Phase: N/A Priority: Normal
NCT ID: NCT04575818 Org: User:
Start: 09/16/20 End: 04/08/21 Due: 04/08/22

An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.

Phase: N/A Priority: Normal
NCT ID: NCT03320876 Org: User:
Start: 07/26/17 End: 06/30/21 Due: 06/30/22

Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02084199 Org: User:
Start: 03/31/14 End: 07/31/14 Due: 07/31/15

Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis

Phase: N/A Priority: Normal
NCT ID: NCT03926195 Org: User:
Start: 05/28/19 End: 05/10/23 Due: 05/10/24

Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)

Phase: N/A Priority: Normal
NCT ID: NCT01894516 Org: User:
Start: 10/08/13 End: 05/29/15 Due: 05/29/16

A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT03689829 Org: User:
Start: 08/13/18 End: 03/02/20 Due: 03/02/21

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04532567 Org: User:
Start: 08/18/20 End: 12/10/20 Due: 12/10/21

A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.

Phase: N/A Priority: Normal
NCT ID: NCT03540524 Org: User:
Start: 05/31/18 End: 03/11/19 Due: 03/11/20

A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT03101670 Org: User:
Start: 03/09/17 End: 03/12/18 Due: 03/12/19

A Study With GLPG1972 in Osteoarthritis Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03311009 Org: User:
Start: 05/15/17 End: 10/25/17 Due: 10/25/18

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT02914561 Org: User:
Start: 10/31/16 End: 11/11/22 Due: 11/11/23

First-in-Human Single and Multiple Dose of GLPG1837

Phase: N/A Priority: Normal
NCT ID: NCT02325037 Org: User:
Start: 12/31/14 End: 09/30/15 Due: 09/30/16

First in Human of Single and Multiple Doses of MOR106

Phase: N/A Priority: Normal
NCT ID: NCT02739009 Org: User:
Start: 04/30/16 End: 08/01/17 Due: 08/01/18

Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT02337608 Org: User:
Start: 12/31/14 End: 11/30/15 Due: 11/30/16

A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Phase: N/A Priority: Normal
NCT ID: NCT04578548 Org: User:
Start: 11/10/20 End: 04/04/23 Due: 04/04/24

This is a Study to Evaluate the Effect of Aging of Multiple Doses of GLPG1205 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03102567 Org: User:
Start: 10/18/16 End: 02/13/17 Due: 02/13/18

Multiple Ascending Dose Study of GLPG0492 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01397370 Org: User:
Start: 07/31/11 End: 12/31/11 Due: 12/31/12

A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

Phase: N/A Priority: Normal
NCT ID: NCT03711162 Org: User:
Start: 11/28/18 End: 03/30/21 Due: 03/30/22

Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT02048618 Org: User:
Start: 02/28/14 End: 02/29/16 Due: 02/28/17

Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06043739 Org: User:
Start: 09/22/23 End: 11/12/23 Due: 11/12/24

A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT04594928 Org: User:
Start: 10/19/20 End: 05/04/21 Due: 05/04/22

Drug-drug Interaction Study with GLPG3667 and Itraconazole in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05272683 Org: User:
Start: 02/28/22 End: 04/22/22 Due: 04/22/23

Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05030857 Org: User:
Start: 09/08/21 End: 11/13/21 Due: 11/13/22